These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 10874445)
21. Pharmacoeconomics and macular degeneration. Brown GC; Brown MM; Brown H; Godshalk AN Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427 [TBL] [Abstract][Full Text] [Related]
22. Study questions increasing cost of intensive care of pneumocystis. AIDS Policy Law; 1995 Feb; 10(2):2. PubMed ID: 11362220 [TBL] [Abstract][Full Text] [Related]
23. [Phamacoeconomic analysis of antibiotics use in the Clinical Center of Vojvodina]. Stefan-Mikić S; Jovanović J; Jovanović N; Aleksić-Dordević M; Cvjetković D; Krajcir I Med Pregl; 2008; 61 Suppl 1():50-8. PubMed ID: 19248640 [TBL] [Abstract][Full Text] [Related]
28. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458 [TBL] [Abstract][Full Text] [Related]
29. [Economic aspects of intensive care medicine--cost and reimbursement according to diagnosis related grouping]. Billing A; Thalhammer M; Eissner HJ; Jauch KW; Inthorn D Zentralbl Chir; 2004 Dec; 129(6):440-6. PubMed ID: 15616906 [TBL] [Abstract][Full Text] [Related]
30. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections. Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294 [TBL] [Abstract][Full Text] [Related]
31. [Economic limits in intensive care. Can we still afford intensive care in the year 2000?]. Barckow D Z Arztl Fortbild Qualitatssich; 2000 Dec; 94(10):828-33; discussion 845. PubMed ID: 11190918 [TBL] [Abstract][Full Text] [Related]
32. [Monitoring of antibiotic treatment of patient with a severe bacterial infection]. Aubert G; Carricajo A Ann Fr Anesth Reanim; 2004 Jul; 23(7):704-13. PubMed ID: 15324959 [TBL] [Abstract][Full Text] [Related]
33. [Main variables in the economic cost of treating an infection]. Grau S Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():41-45. PubMed ID: 28129821 [TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital. Patel GW; Duquaine SM; McKinnon PS Pharmacotherapy; 2007 Dec; 27(12):1637-43. PubMed ID: 18041884 [TBL] [Abstract][Full Text] [Related]
35. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study]. Codina C; Miró JM; Tuset M; Claramonte J; Gomar C; Gotsens R; Gómez B; Suárez S; Abellana R; Ascaso C; Cartaña R; Rodríguez E; Asenjo M; Carné X; Trilla A; Marco F; Gómez J; Brunet M; Pomar JL; Gatell JM; Ribas J Med Clin (Barc); 2000; 114 Suppl 3():54-61. PubMed ID: 10994565 [TBL] [Abstract][Full Text] [Related]
36. Effectiveness and efficiency of intensive care medicine: variable costs in different diagnosis groups. Iapichino G; Radrizzani D; Simini B; Rossi C; Albicini M; Ferla L; Colombo A; Pezzi A; Brazzi L; Melotti R; Rossi G; Acta Anaesthesiol Scand; 2004 Aug; 48(7):820-6. PubMed ID: 15242425 [TBL] [Abstract][Full Text] [Related]
37. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. Smith PK; Datta SK; Muhlbaier LH; Samsa G; Nadel A; Lipscomb J Ann Thorac Surg; 2004 Feb; 77(2):635-42; discussion 642-3. PubMed ID: 14759451 [TBL] [Abstract][Full Text] [Related]
38. [Ethics of antibiotherapy in geriatric medicine]. Michel JP; Loew F; Brennenstuhl P; Zelger G; Courvoisier B Schweiz Med Wochenschr; 1994 Dec; 124(49):2220-5. PubMed ID: 7801081 [TBL] [Abstract][Full Text] [Related]